

Q 1654
Rhu

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: SZARDENINGS, et al.
 Serial No.: 09/674,733
 Filed: May 2, 2001
 For: MELANOCORTIN 1 RECEPTOR SELECTIVE COMPOUNDS
 Confirmation No.: 3759

U.S. Patent and Trademark Office
 2011 South Clark Place
 Customer Window
 Crystal Plaza Two, Lobby, Room 1B03
 Arlington, Virginia 22202



Art Unit: 1654
 Examiner: CHISM, B.
 Washington, D.C.
 Atty.'s Docket: SZARDENINGS-1
 Date: July 21, 2004

Sir:
 Transmitted herewith is an [XX] Amendment [XX] Research Report and Substitute Power of Attorney in the above-identified application.

[] Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.
 [] A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
 [] No additional fee is required.

07/22/2004 HAL111 0000085 09674733

01 FC:1253 950.00 OP

The fee has been calculated as shown below:
 (Col. 1) (Col. 2) (Col. 3)

	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra		Rate	Additional Fee		Rate	Additional Fee
Total	38	Minus	64	0		x 9	\$		x18	\$
Indep.	3	Minus	3	0		x43	\$		x86	\$
First Presentation of Multiple Dependent Claim										
TOTAL ADDITIONAL CLAIMS FEE										
\$										

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
 ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
 *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col.1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time
 If any extension of time for a response is required applicant requests that this be considered a petit

[XX] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity
 Response Filed Within
 [] First - \$ 55.00
 [] Second - \$ 210.00
 [] Third - \$ 475.00
 [] Fourth - \$ 740.00
 [] Fifth - \$1005.00

Other Than Small Entity
 Response Filed Within
 [] First - \$ 110.00
 [] Second - \$ 420.00
 [XX] Third - \$ 950.00
 [] Fourth - \$1480.00
 [] Fifth - \$2010.00

[] Less fees (\$) already paid for months extension of time on

[] Please charge my Deposit Account No. 02-4035 in the amount of \$. A duplicate copy of this sheet is attached.

[] A check in the amount of \$ is attached (check no.).

[XX] Credit Card Payment Form, PTO-2038, authorizing payment in the amount of \$950.00 is attached.

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR Section 1.16 and all patent processing fees under 37 CFR Section 1.17 throughout the prosecution of the case.


This blanket authorization does not include patent issue fees under 37 CFR Section 1.18.

BROWDY AND NEIMARK, P.L.L.C.
 Attorneys for Applicant(s)

Facsimile: (202) 737-3528
 Telephone: (202) 628-5197

By:

IVER P. COOPER
 Registration No. 28,005



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:) Art Unit: 1654
SZARDENINGS, et al.) Examiner: CHISM, B.
Serial No.: 09/674,733) Washington, D.C.
Filed: May 2, 2001) July 21, 2004
For: MELANOCORTIN 1 RECEPTOR) Docket No.: SZARDENINGS=1
SELECTIVE COMPOUNDS) Confirmation No.: 3759

AMENDMENT UNDER RULE 1.115

U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202

S i r :

In response to the office action mailed January 28, 2004,
please enter the following amendments and remarks.

Amendments to the Claims are reflected in the listing of claims
which begins on page 2 of this paper.

Remarks begin on page 11 of this paper.